Compound ID | 454
NB3352 (NB2030 analogue)
Class: Cephalosporin-triclosan
| Spectrum of activity: | Gram-negative |
| Details of activity: | Improved in vivo activity compared with NB2030 but also have reduced in vitro antibacterial activity |
| Description: | Li Q, Doppalapudi VR, Castillo R, et al. Analogs of NB2030, a Cephalosporin-triclosan conjugate, with reduced serum protein binding capacity. 43rd-ICAAC 2003;268 |
| Institute where first reported: | New Biotics (Kiadis Pharmaceuticals, Netherlands) |
| Year first mentioned: | 2003 |
| Highest developmental phase: | Preclinical |
| Development status: | Inactive |
| External links: | |
| Citation: |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.